Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer

The combination of endocrine therapy (ET) and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (CDK4/6i) was a hallmark in metastatic luminal breast cancer (BC). However, intrinsic and acquired resistance affects long-term efficacy. Here, we study the role of the receptor activator of nuclear factor-...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomes, Inês, Gallego-Paez, Lina M., Jiménez, Maria, Santamaria, Patricia G., Mansinho, André, Sousa, Rita, Abreu, Catarina, Suárez, Eva González, Costa, Luis, Casimiro, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439176/
https://www.ncbi.nlm.nih.gov/pubmed/37451269
http://dx.doi.org/10.1016/j.xcrm.2023.101120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439176/
https://www.ncbi.nlm.nih.gov/pubmed/37451269
http://dx.doi.org/10.1016/j.xcrm.2023.101120

Ejemplares similares